Ponatinib vs. Imatinib as Frontline Treatment for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Matching Adjusted Indirect Comparison
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource, 1 online resource.
- Language
-
Englisch
- Bibliographic citation
-
Ponatinib vs. Imatinib as Frontline Treatment for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Matching Adjusted Indirect Comparison ; volume:40 ; number:7 ; day:19 ; month:5 ; year:2023 ; pages:3087-3103 ; date:7.2023
Advances in therapy ; 40, Heft 7 (19.5.2023), 3087-3103, 7.2023
- Creator
-
Ribera, Josep-Maria
Prawitz, Thibaud
Freitag, Andreas
Sharma, Anuj
Dobi, Balázs
Rizzo, Federica
Sabatelli, Lorenzo
Patos, Petros
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s12325-023-02497-y
- URN
-
urn:nbn:de:101:1-2023092112515394496309
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:55 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Ribera, Josep-Maria
- Prawitz, Thibaud
- Freitag, Andreas
- Sharma, Anuj
- Dobi, Balázs
- Rizzo, Federica
- Sabatelli, Lorenzo
- Patos, Petros
- SpringerLink (Online service)
Other Objects (12)
Two-stage matching-adjusted indirect comparison
Matching-Adjusted Indirect Comparison of Blinatumomab vs. Inotuzumab Ozogamicin for Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia
Correction: Two-stage matching-adjusted indirect comparison
Targeting IL-17A enhances imatinib efficacy in Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia
A Critical Appraisal of Matching-Adjusted Indirect Comparisons in Spinal Muscular Atrophy
Frontline Ph-negative B-cell precursor acute lymphoblastic leukemia treatment and the emerging role of blinatumomab
Everolimus and sunitinib for advanced pancreatic neuroendocrine tumors: a matching-adjusted indirect comparison
Last frontline, 6
Last frontline, 4
Last frontline, 5
Last frontline, 1
Last frontline, 3
Two-stage matching-adjusted indirect comparison
Matching-Adjusted Indirect Comparison of Blinatumomab vs. Inotuzumab Ozogamicin for Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia
Correction: Two-stage matching-adjusted indirect comparison
Targeting IL-17A enhances imatinib efficacy in Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia
A Critical Appraisal of Matching-Adjusted Indirect Comparisons in Spinal Muscular Atrophy
Frontline Ph-negative B-cell precursor acute lymphoblastic leukemia treatment and the emerging role of blinatumomab
Everolimus and sunitinib for advanced pancreatic neuroendocrine tumors: a matching-adjusted indirect comparison
Last frontline, 6
Last frontline, 4
Last frontline, 5
Last frontline, 1
Last frontline, 3
Two-stage matching-adjusted indirect comparison
Matching-Adjusted Indirect Comparison of Blinatumomab vs. Inotuzumab Ozogamicin for Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia
Correction: Two-stage matching-adjusted indirect comparison
Targeting IL-17A enhances imatinib efficacy in Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia
A Critical Appraisal of Matching-Adjusted Indirect Comparisons in Spinal Muscular Atrophy
Frontline Ph-negative B-cell precursor acute lymphoblastic leukemia treatment and the emerging role of blinatumomab
Everolimus and sunitinib for advanced pancreatic neuroendocrine tumors: a matching-adjusted indirect comparison
Last frontline, 6
Last frontline, 4
Last frontline, 5
Last frontline, 1